Cervical Cancer Diagnostic Tests Market
Cervical Cancer Diagnostic Tests Market (Tests (Pap Smear tests, Colposcopy, HPV Testing, Endocervical Curettage (ECC) and Others (Cone Biopsy and Loop Electrosurgical Excision Procedure (LEEP)) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020
Press Release :
Cervical Cancer Diagnostic Tests Market: Snapshot
Advances in screening methods in cervical cytology along with increasing implementation of cervical screening programs, particularly in developing economies, are key to high growth momentum in the cervical cancer diagnostics tests market. Cervical cancer is associated with high mortality rate in such economies. Growing numbers of people who became newly infected with HIV in the past couple years have triggered the need for cervical cancer diagnostic tests. According to 2018 update by the WHO, cervical cancer is the fourth most frequent cancer in women, with a majority of mortality found in low- and middle-income countries in recent years. Efforts of governments in increasing access to screening programs are broadening the outlook of the market.
The global cervical cancer diagnostic tests market is expected to garner a healthy 6.10% CAGR during 2014 - 2020. The market stood at US$5.9 bn in 2013 and is projected to reach worth of US$8.9 bn by 2020-end.
Demand for Pap Tests Widespread for Detecting Potentially Precancerous Cells
The report segments the cancer diagnostic tests market on the basis of type of test and region. Major types of tests in cervical cancer are Pap smear tests, human papilloma virus (HPV) testing, colopscopy, and endocervical curettage (ECC) procedure, and an others segment. The others segment include loop electrosurgical excision procedure (LEEP) and cone biopsy. Of these, HPV testing and Pap tests have been popularly used in the diagnosis of cervical cancer for entirely different reasons. Pap tests have become popular in detecting potentially precancerous and cancerous processes, notably before more sensitive screening methods are used in cervical cancer patients.
The HPV segment is anticipate to expand at 8% CAGR between 2014 and 2020. The Pap smear tests segment is projected to clock a CAGR of more than 6% during 2014 – 2020. To a great deal, opportunities in the segment have thrived due to increased focus on early detection of cervical cancer. The tests are used in early detection of glandular cell abnormalities.
Improvement in diagnostic technology for detecting pre-cancerous lesions catalyzed demand for both types of tests in the cervical cancer diagnostic tests market. Growing incidences of cervical cancer and growing awareness about the disease will likely advance the market potential of colopscopy, ECC, and LEEP tests for diagnosing cervical cancer tests.
Increased Penetration of Screening Programs Cemented Growth in North America
The various regional markets for cervical cancer diagnostic tests are North America, Asia Pacific, Rest of the World, and Europe. Of all the regions, North America held the majority of share in 2013. Growing participation of regional populations in screening programs over the past few years had helped the regional market attain a prominent share. This has led to decreasing incidence of cervical cancer mortality. Further, substantial efforts have been made by public health systems to update guidelines for diagnosing cervical cancer.
Meanwhile, Asia Pacific is presenting large lucrative avenue. The demand for cervical cancer diagnostic tests has risen on the back of the growing initiatives by governments to reduce the heal burden and mortality rate due to cancer. The high unmet need for screening technologies in numerous countries is catalyzing the overall growth of this regional market.